L-type amino acid transporter 1 expression is highly correlated with Gleason score in prostate cancer

Segawa,Atsuki; Nagamori,Shushi; Kanai,Yoshikatsu; Masawa,Nobuhide; Oyama,Tetsunari

doi:10.3892/mco.2012.54

L-type amino acid transporter 1 expression is highly correlated with Gleason score in prostate cancer

Authors:
- Atsuki Segawa
- Shushi Nagamori
- Yoshikatsu Kanai
- Nobuhide Masawa
- Tetsunari Oyama
View Affiliations

Affiliations: Department of Diagnostic Pathology, Gunma University Graduate School of Medicine, Maebashi, Gunma 371-8512, Japan, Division of Bio-system Pharmacology, Department of Pharmacology, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, Japan, Department of Pathology, Dokkyo University School of Medicine, Mibu, Tochigi 321-0293, Japan
Published online on: December 20, 2012 https://doi.org/10.3892/mco.2012.54
Pages: 274-280

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Upregulation of L‑type amino acid transporter 1 (LAT1), a member of the system L amino acid transporter family, may be detected by immunohistochemical methods. Immunoreactive LAT1 expression in prostate cancer is considered to be a promising biomarker for high‑grade malignancy. However, the mutual association between LAT1 and Gleason score, the most fixed indicator for grading the malignancy of prostate cancers, remains to be elucidated. The aim of this study was to clarify the correlations between LAT1 and other factors in prostate cancer, including the Gleason score. We evaluated 54 cases of primary prostate cancer, surgically resected without any neoadjuvant therapies and performed immunohistochemistry for LAT1, Ki‑67, CD34 and vascular endothelial growth factor on the tissue sections. The Gleason score as well as the age, pathological stage (pStage) of prostate cancer and serum concentration of prostate‑specific antigen (PSA) of each case were also assessed. Statistical analysis for the correlations between LAT1 expression and Gleason score and each of the other characteristics studied was performed. As a result, a strong significant correlation between immunoreactive LAT1 expression and Gleason score was identified (P<0.01). We concluded that immunoreactive LAT1 expression in tissue sections of prostate cancer may be useful as a biomarker for high‑grade malignancy.

View Figures

View References

1	Matsuda T and Saika K: Comparison of time trends in prostate cancer incidence (1973–2002) in Asia, from cancer incidence in five continents, Vols IV–IX. Jpn J Clin Oncol. 39:468–469. 2009.
2	Kanai Y, Segawa H, Miyamoto K, Uchino H, Takeda E and Endou H: Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J Biol Chem. 273:23629–23632. 1998. View Article : Google Scholar : PubMed/NCBI
3	Meier C, Ristic Z, Klauser S and Verrey F: Activation of system L heterodimeric amino acid exchangers by intracellular substrates. EMBO J. 21:580–589. 2002. View Article : Google Scholar : PubMed/NCBI
4	Yanagida O, Kanai Y, Chairoungdua A, et al: Human L-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines. Biochim Biophys Acta. 1514:291–302. 2001. View Article : Google Scholar : PubMed/NCBI
5	Fuchs BC and Bode BP: Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime? Semin Cancer Biol. 15:254–266. 2005. View Article : Google Scholar : PubMed/NCBI
6	Yamauchi K, Sakurai H, Kimura T, Wiriyasermkul P, Nagamori S, Kanai Y and Kohno N: System L amino acid transporter inhibitor enhances anti-tumor activity of cisplatin in a head and neck squamous cell carcinoma cell line. Cancer Lett. 276:95–101. 2009. View Article : Google Scholar : PubMed/NCBI
7	Sakata T, Ferdous G, Tsuruta T, et al: L-type amino-acid transporter 1 as a novel biomarker for high-grade malignancy in prostate cancer. Pathol Int. 59:7–18. 2009. View Article : Google Scholar : PubMed/NCBI
8	Kim DK, Ahn SG, Park JC, et al: Expression of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (4F2hc) in oral squamous cell carcinoma and its precursor lesion. Anticancer Res. 24:1671–1675. 2004.PubMed/NCBI
9	Kobayashi H, Ishii Y and Takayama T: Expression of L-type amino acid transporter 1 (LAT1) in esophageal carcinoma. J Surg Oncol. 90:233–238. 2005. View Article : Google Scholar : PubMed/NCBI
10	Nawashiro H, Otani N, Shinomiya N, et al: L-type amino acid transporter 1 as a potential molecular target in human astrocytic tumors. Int J Cancer. 119:484–492. 2006. View Article : Google Scholar : PubMed/NCBI
11	Nakanishi K, Ogata S, Matsuo H, et al: Expression of LAT1 predicts risk of progression of transitional cell carcinoma of the upper urinary tract. Virchows Arch. 451:681–690. 2007. View Article : Google Scholar : PubMed/NCBI
12	Kaira K, Oriuchi N, Imai H, et al: Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I–III non-small cell lung cancer. Br J Cancer. 98:742–748. 2008.
13	Takeuchi K, Ogata S, Nakanishi K, et al: LAT1 expression in non-small cell lung carcinomas: analyses by semiquantitative reverse transcription-PCR (237 cases) and immunohistochemistry (295 cases). Lung Cancer. 68:58–65. 2010. View Article : Google Scholar : PubMed/NCBI
14	Furuya M, Horiguchi J, Nakajima H, Kanai Y and Oyama T: Correlation of L-type amino acid transporter 1 and CD98 expression with triple negative breast cancer prognosis. Cancer Sci. 103:382–389. 2012. View Article : Google Scholar : PubMed/NCBI
15	Kaira K, Sunose Y, Segawa A, et al: Prognostic significance of L-type amino acid transporter 1 expression in surgically resected pancreatic cancer. Br J Cancer. 107:632–638. 2012. View Article : Google Scholar : PubMed/NCBI
16	Sobin LH, Gospodarowicz MK and Wittekind C: TNM Classification of Malignant Tumors (UICC International Union Against Cancer). 7th edition. Wiley-Blackwell; Oxford: 2009
17	Epstein JI, Allsbrook WC Jr, Amin MB and Egevad LL; ISUP Grading Committee: The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol. 29:1228–1242. 2005. View Article : Google Scholar : PubMed/NCBI
18	Buck AC, Schirrmeister HH, Guhlmann CA, et al: Ki-67 immunostaining in pancreatic cancer and chronic active pancreatitis: does in vivo FDG uptake correlate with proliferative activity? J Nucl Med. 42:721–725. 2001.PubMed/NCBI
19	Weidner N, Semple JP, Welch WR and Folkman J: Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med. 324:1–8. 1991. View Article : Google Scholar : PubMed/NCBI
20	Kaira K, Oriuchi N, Imai H, et al: Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in stage I pulmonary adenocarcinoma. Lung Cancer. 66:120–126. 2009. View Article : Google Scholar
21	D’Amico AV, Whittington R, Malkowicz SB, et al: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 280:969–974. 1998.
22	Stark JR, Perner S, Stampfer MJ, et al: Gleason score and lethal prostate cancer: does 3+4=4+3? J Clin Oncol. 27:3459–3464. 2009.PubMed/NCBI
23	Wright JL, Salinas CA, Lin DW, Kolb S, Koopmeiners J, Feng Z and Stanford JL: Prostate cancer specific mortality and Gleason 7 disease differences in prostate cancer outcomes between cases with Gleason 4+3 and Gleason 3+4 tumors in a population-based cohort. J Urol. 182:2702–2707. 2009.
24	Laitinen S, Martikainen PM, Tolonen T, Isola J, Tammela T and Visakorpi T: EZH2, Ki-67 and MCM7 are prognostic markers in prostatectomy-treated patients. Int J Cancer. 122:595–602. 2008. View Article : Google Scholar : PubMed/NCBI
25	Mastroberardino L, Spindler B, Pfeiffer R, et al: Amino-acid transport by heterodimers of 4F2hc/CD98 and members of a permease family. Nature. 395:288–291. 1998. View Article : Google Scholar : PubMed/NCBI
26	Kim DK, Kanai Y, Matsuo H, et al: The human T-type amino acid transporter-1: characterization, gene organization, and chromosomal location. Genomics. 79:95–103. 2002. View Article : Google Scholar : PubMed/NCBI